Fernanda Augustini Rigon1, Marcelo Fernando Ronsoni1, Alexandre Hohl1, Simone van de Sande-Lee2,3. 1. Serviço de Endocrinologia e Metabologia, Hospital Universitário Polydoro Ernani de São Thiago (HU-UFSC), Florianópolis, SC, Brazil. 2. Serviço de Endocrinologia e Metabologia, Hospital Universitário Polydoro Ernani de São Thiago (HU-UFSC), Florianópolis, SC, Brazil. simonevslee@hotmail.com. 3. Departamento de Clínica Médica, Hospital Universitário, 3 andar, Universidade Federal de Santa Catarina (UFSC), Florianópolis, Santa Catarina, 88040-970, Brazil. simonevslee@hotmail.com.
Abstract
INTRODUCTION: The prevalence of obesity has grown exponentially over the last several decades. Research has linked male obesity to changes in the gonadal axis, which can induce functional hypogonadism. Bariatric surgery provides sustained weight loss and metabolic improvement. This was a retrospective cohort study to evaluate the male gonadal axis and metabolic profiles of obese individuals during the bariatric pre- and post-operative periods while comparing them to a normal body mass index (BMI) group. METHODS: Twenty-nine obese men, who underwent bariatric surgery between 2012 and 2016 at the Federal University of Santa Catarina Hospital and a control group (CG) of 29 age-matched men with normal BMI, were analyzed. Bariatric pre- and 6-month post-operative data were compared with the CG. RESULTS: The study group (G1) presented an average age, weight, and BMI of 42.8 ± 9.5 years, 155.2 ± 25.8 kg, and 50.6 ± 7.1 kg/m2, respectively. The pre-operative total testosterone (TT) G1 values were different from the CG (229.5 ± 96.4 versus 461.5 ± 170.8 ng/dL, p < 0.01). Bariatric surgery promoted a statistically significant improvement in weight, TT, and metabolic profiles in surgical patients. CONCLUSION: Functional hypogonadism is prevalent in obese men, and we must be aware of this diagnosis. Although studies defining the best diagnostic parameters and indication of adequate hormone replacement therapy are lacking, an increase in TT levels during the first 6 months after bariatric surgery was identified in our study. Previous studies have shown that gonadal function can normalize after metabolic improvement.
INTRODUCTION: The prevalence of obesity has grown exponentially over the last several decades. Research has linked male obesity to changes in the gonadal axis, which can induce functional hypogonadism. Bariatric surgery provides sustained weight loss and metabolic improvement. This was a retrospective cohort study to evaluate the male gonadal axis and metabolic profiles of obese individuals during the bariatric pre- and post-operative periods while comparing them to a normal body mass index (BMI) group. METHODS: Twenty-nine obesemen, who underwent bariatric surgery between 2012 and 2016 at the Federal University of Santa Catarina Hospital and a control group (CG) of 29 age-matched men with normal BMI, were analyzed. Bariatric pre- and 6-month post-operative data were compared with the CG. RESULTS: The study group (G1) presented an average age, weight, and BMI of 42.8 ± 9.5 years, 155.2 ± 25.8 kg, and 50.6 ± 7.1 kg/m2, respectively. The pre-operative total testosterone (TT) G1 values were different from the CG (229.5 ± 96.4 versus 461.5 ± 170.8 ng/dL, p < 0.01). Bariatric surgery promoted a statistically significant improvement in weight, TT, and metabolic profiles in surgical patients. CONCLUSION:Functional hypogonadism is prevalent in obesemen, and we must be aware of this diagnosis. Although studies defining the best diagnostic parameters and indication of adequate hormone replacement therapy are lacking, an increase in TT levels during the first 6 months after bariatric surgery was identified in our study. Previous studies have shown that gonadal function can normalize after metabolic improvement.
Authors: Majid Ezzati; Alan D Lopez; Anthony Rodgers; Stephen Vander Hoorn; Christopher J L Murray Journal: Lancet Date: 2002-11-02 Impact factor: 79.321
Authors: Abdelouahid Tajar; Gianni Forti; Terence W O'Neill; David M Lee; Alan J Silman; Joseph D Finn; György Bartfai; Steven Boonen; Felipe F Casanueva; Aleksander Giwercman; Thang S Han; Krzysztof Kula; Fernand Labrie; Michael E J Lean; Neil Pendleton; Margus Punab; Dirk Vanderschueren; Ilpo T Huhtaniemi; Frederick C W Wu Journal: J Clin Endocrinol Metab Date: 2010-02-19 Impact factor: 5.958
Authors: Sandeep Dhindsa; Michael G Miller; Cecilia L McWhirter; Donald E Mager; Husam Ghanim; Ajay Chaudhuri; Paresh Dandona Journal: Diabetes Care Date: 2010-03-03 Impact factor: 19.112
Authors: Mariel M Finucane; Gretchen A Stevens; Melanie J Cowan; Goodarz Danaei; John K Lin; Christopher J Paciorek; Gitanjali M Singh; Hialy R Gutierrez; Yuan Lu; Adil N Bahalim; Farshad Farzadfar; Leanne M Riley; Majid Ezzati Journal: Lancet Date: 2011-02-03 Impact factor: 79.321
Authors: Gary Whitlock; Sarah Lewington; Paul Sherliker; Robert Clarke; Jonathan Emberson; Jim Halsey; Nawab Qizilbash; Rory Collins; Richard Peto Journal: Lancet Date: 2009-03-18 Impact factor: 79.321
Authors: Pilar Cobeta; Roberto Pariente; Alvaro Osorio; Marta Marchan; Marta Cuadrado-Ayuso; David Pestaña; Julio Galindo; José I Botella-Carretero Journal: Biomedicines Date: 2022-08-17
Authors: Hannes Beiglböck; Paul Fellinger; Tamara Ranzenberger-Haider; Bianca Itariu; Gerhard Prager; Alexandra Kautzky-Willer; Michael Krebs; Peter Wolf Journal: Obes Surg Date: 2020-06-13 Impact factor: 4.129